![]() |
市場調查報告書
商品編碼
1503301
到 2030 年 PRP(富血小板血漿)市場預測:按來源類型、類型、應用、最終用戶和地區進行的全球分析Platelet Rich Plasma (PRP) Market Forecasts to 2030 - Global Analysis By Origin Type (Autologous, Homologous and Allogeneic), Type (Leukocyte-rich PRP, Leukocyte-rich Fibrin and Other Types), Application, End User and By Geography |
根據Stratistics MRC預測,2024年全球PRP(富血小板血漿)市場規模將達到8.639億美元,預測期內複合年成長率為17.3%,預計到2030年將達到22.505億美元。
富血小板血漿 (PRP) 療法使用患者自身血漿的濃縮形式來促進癒合和組織再生。治療方法首先從患者體內抽取少量血液,然後將其在離心機中旋轉,以將血小板和血漿與其他血液成分分離。血小板是小血細胞,對於血塊形成至關重要,並且含有促進體內癒合過程的生長因子。將濃縮的富含血小板的血漿注射到患者的受影響區域,如關節、肌腱和皮膚,以促進組織修復和再生。
根據 2020 年《採血針》發表的一篇論文,骨關節炎影響著全球 7% 的人口,即全球超過 5 億人,其中女性受到的影響尤其嚴重。
整形外科疾病增加
PRP(富血小板血漿)療法包括從患者自身血液中提取和濃縮血小板,並將其注射到受影響的區域以促進癒合和組織再生。骨關節炎、肌腱炎和韌帶損傷等整形外科疾病變得越來越常見,尤其是老年人和運動員。 PRP 的吸引力在於其微創性,以及為手術和長期藥物等更具侵入性的治療提供替代方案的潛力。此外,越來越多的臨床證據支持 PRP 在整形外科中的使用,證明其在促進組織修復和減輕疼痛方面的有效性。
有限的臨床證據
PRP(富血小板血漿)市場主要面臨限制,因為臨床證據不足以支持其在各種醫療應用中的有效性。儘管 PRP 很受歡迎並具有潛在的好處,但缺乏可靠的臨床試驗和標準化通訊協定阻礙了其在許多地區的普及和監管核准。臨床醫生和監管機構需要精心設計的研究來證明明確的療效、安全性和長期結果,才能自信地將 PRP 納入主流醫療實踐。然而,製備方法和患者特異性反應的差異進一步使通用治療指南的建立變得複雜。
日益成長的體育和健身活動
PRP療法將患者自身的血小板濃縮並注射到受傷部位以促進癒合,現在已受到運動員和健身愛好者的歡迎。這主要是因為它可以加速肌腱炎、肌肉拉傷和關節損傷等運動傷害的恢復。隨著越來越多的人參與運動和健身,對有效且快速恢復方法的需求不斷增加,導致 PRP 治療的採用率不斷增加。
成本考慮
PRP 療法涉及從患者自身血液中提取和濃縮血小板,但由於需要專門的設備和訓練有素的人員,因此價格昂貴。由於缺乏標準化的定價模型和保險範圍的變化,這些費用變得更加複雜,使得許多潛在患者無法負擔 PRP 治療。由於臨床結果參差不齊,而且缺乏關於 PRP 療法對特定疾病有效性的確鑿證據,醫療保健提供者和患者對投資 PRP 療法猶豫不決。
COVID-19 大流行對 PRP(富血小板血漿)市場產生了重大影響,影響了需求和供應動態。最初,市場因大範圍關閉而面臨混亂,導致包括 PRP 治療在內的選擇性手術減少。許多診所和醫療機構暫時關閉或限制服務,減少了接受 PRP 注射等非緊急治療的患者就診次數。此外,運輸和分銷鏈中的物流挑戰進一步阻礙了 PRP 產品的供應。然而,隨著醫療保健系統適應大流行並優先考慮安全的選擇性手術,PRP 市場顯示出復甦的跡象。
預計該行業在預測期內將是最大的。
由於其在各種醫療和美容應用中的安全性和功效,同源細分市場預計將在預測期內成為最大的細分市場。透過利用患者自身的血小板、生長因子和細胞激素,PRP 療法可以促進組織修復、減少發炎並增強自然癒合過程。此外,隨著技術和研究的進步,PRP的應用範圍正在從整形外科擴展到皮膚科、牙科和美容外科,進一步推動市場成長。 PRP 治療的同源性不僅可以改善患者的治療效果,還可以增強醫療保健提供者和患者對其安全性和治療潛力的信心,從而有助於市場擴張。
神經病學預計在預測期內具有最高的複合年成長率
神經病學預計在預測期內複合年成長率最高。在神經病學中,PRP(富血小板血漿)療法是將患者自身濃縮血漿注射到神經系統受影響的區域,以促進癒合和再生。 PRP 含有高濃度的血小板,並富含刺激組織修復和再生的生長因子。在神經病學領域,PRP 在治療周邊神經損傷、脊髓損傷以及帕金森氏症和阿茲海默症神經退化性疾病方面顯示出良好的前景。這種治療方法可以加速身體的自然癒合過程,減少發炎並恢復受損神經組織的功能。
預計期間,北美地區佔據最大的市場佔有率。隨著老年人口的增加,可透過 PRP 治療治療的疾病的盛行率也在增加,例如骨關節炎、慢性肌腱病變和其他肌肉骨骼疾病。 PRP 源自於患者自身的血液,因其據稱能夠刺激組織修復和減少發炎而受到越來越多的追捧,並且受到全部區域厭惡侵入性手術的老年人的追捧,這提供了一種特別有吸引力的非手術選擇。
預計歐洲地區在預測期內將呈現良好的成長動能。政府法規確保 PRP 療法在銷售或臨床使用之前符合嚴格的功效和安全標準。透過實施嚴格監控,歐洲當局降低了與 PRP 治療相關的風險,例如污染和產品品質不一致。此外,法律規範將促進 PRP 技術的研究和開發,促進創新並改善全部區域的治療結果。 PRP 監管的結構化方法不僅可以保護患者健康,還可以增加醫療保健提供者和患者之間的信任,鼓勵全部區域各個醫療領域廣泛採用 PRP 治療。
According to Stratistics MRC, the Global Platelet Rich Plasma (PRP) Market is accounted for $863.9 million in 2024 and is expected to reach $2,250.5 million by 2030 growing at a CAGR of 17.3% during the forecast period. Platelet Rich Plasma (PRP) therapy involves using a concentrated form of a patient's own blood plasma to promote healing and tissue regeneration. This procedure begins with drawing a small amount of blood from the patient, which is then spun in a centrifuge to separate the platelets and plasma from other blood components. Platelets are tiny blood cells crucial for clot formation and contain growth factors that facilitate healing processes in the body. Once concentrated, this platelet-rich plasma is injected back into the patient's affected area, such as joints, tendons, or skin, where it stimulates tissue repair and regeneration.
According to the article published in the Lancet Journal in 2020, osteoarthritis affects 7% of the global population, more than 500 million people worldwide, with women disproportionately affected by the condition.
Increasing prevalence of orthopedic disorders
Platelet Rich Plasma therapy involves the extraction and concentration of platelets from a patient's own blood, which are then injected into the affected area to accelerate healing and tissue regeneration. Orthopedic conditions such as osteoarthritis, tendonitis, and ligament injuries are increasingly common, particularly among aging populations and athletes. PRP's appeal lies in its minimally invasive nature and potential to offer an alternative to more invasive treatments like surgery or long-term medication. Moreover, its use in orthopedics is supported by a growing body of clinical evidence demonstrating its effectiveness in promoting tissue repair and reducing pain.
Limited clinical evidence
The Platelet Rich Plasma (PRP) market faces limitations primarily due to insufficient clinical evidence supporting its efficacy across various medical applications. Despite its popularity and potential benefits, the lack of robust clinical trials and standardized protocols hinders widespread adoption and regulatory approval in many regions. Clinicians and regulatory bodies require well-designed studies demonstrating clear efficacy, safety profiles, and long-term outcomes to confidently integrate PRP into mainstream medical practices. However, variability in preparation methods and patient-specific responses further complicate the establishment of universal treatment guidelines.
Growing sports and physical fitness activities
PRP therapy, which involves injecting a concentration of a patient's own platelets into injured areas to promote healing, has gained popularity among athletes and fitness enthusiasts. This is primarily due to its potential to accelerate recovery from sports injuries such as tendonitis, muscle strains, and joint injuries. As more individuals engage in sports and fitness routines, there is an increasing demand for effective and swift recovery methods, driving the adoption of PRP therapy.
Cost considerations
PRP therapy involves extracting and concentrating platelets from a patient's own blood, which requires specialized equipment and trained personnel, thus driving up costs. These expenses are further compounded by the lack of standardized pricing models and insurance coverage variability, making PRP treatments unaffordable for many potential patients. The variability in clinical outcomes and the perceived lack of definitive evidence regarding its efficacy for certain conditions can deter healthcare providers and patients from investing in PRP therapy.
The COVID-19 pandemic significantly impacted the Platelet Rich Plasma (PRP) market, affecting both demand and supply dynamics. Initially, the market faced disruptions due to widespread lockdowns, which led to a reduction in elective procedures, including those involving PRP therapy. Many clinics and healthcare facilities temporarily closed or limited their services, causing a decline in patient visits for non-urgent treatments like PRP injections. Moreover, logistical challenges in transportation and distribution chains further hindered the availability of PRP products. However, as healthcare systems adapted to the pandemic and began to prioritize safe elective procedures, the PRP market showed signs of recovery.
The Homologous segment is expected to be the largest during the forecast period
Homologous segment is expected to be the largest during the forecast period due to its safety profile and effectiveness in various medical and aesthetic applications. By utilizing the patient's own platelets, growth factors, and cytokines, PRP therapies can promote tissue repair, reduce inflammation, and enhance healing processes naturally. Moreover, advancements in technology and research have expanded the applications of PRP beyond orthopedics to dermatology, dentistry, and cosmetic procedures, further driving market growth. The homologous nature of PRP treatments not only enhances patient outcomes but also contributes to the market's expansion by fostering confidence among healthcare providers and patients alike in its safety and therapeutic potential.
The Neurology segment is expected to have the highest CAGR during the forecast period
Neurology segment is expected to have the highest CAGR during the forecast period. Platelet Rich Plasma (PRP) therapy in neurology involves injecting a concentrated form of a patient's own blood plasma into affected areas of the nervous system to promote healing and regeneration. PRP contains a high concentration of platelets, which are rich in growth factors that stimulate tissue repair and regeneration. In neurology, PRP has shown promise in treating conditions such as peripheral nerve injuries, spinal cord injuries, and neurodegenerative diseases like Parkinson's and Alzheimer's. The therapy aims to enhance the body's natural healing processes, reduce inflammation, and potentially restore function to damaged nerve tissues.
North America region commanded the largest market share over the extrapolated period. As the elderly demographic grows, so does the prevalence of conditions such as osteoarthritis, chronic tendinopathy, and other musculoskeletal disorders that PRP therapy can potentially address across the region. PRP, derived from a patient's own blood, is increasingly sought after for its purported ability to stimulate tissue repair and reduce inflammation, offering a non-surgical option particularly appealing to older individuals wary of invasive procedures throughout the region.
Europe region is estimated to witness profitable growth during the forecasted period. Government regulations ensure that PRP therapies meet strict efficacy and safety criteria before they can be marketed or used clinically. By enforcing rigorous oversight, European authorities mitigate risks associated with PRP treatments, such as contamination and inconsistent product quality. Moreover, regulatory frameworks promote research and development in PRP technologies, fostering innovation and improving treatment outcomes across the region. The structured approach to PRP regulation not only safeguards patient health but also enhances confidence among healthcare providers and patients alike, encouraging broader adoption of PRP therapies across various medical disciplines throughout the region.
Key players in the market
Some of the key players in Platelet Rich Plasma (PRP) market include AdiStem Ltd, Arthrex, Inc, Cellular Biomedicine Group, Inc, Cesca Therapeutics Inc, EmCyte Corporation, Exactech, Inc, Global Human Biomaterials Inc, Harvest Technologies, Nuo Therapeutics, Inc, Stryker Corporation, Synthetic Blood International, Inc and Terumo Corporation.
In December 2023, Hairline International Hair and Skin Clinic, the hair clinic, announced the launch of an advanced hair regeneration therapy called Sonicated PRP, based on groundbreaking research utilizing platelet-rich plasma (PRP). The cutting-edge treatment, aims to revolutionize hair follicle activation and regeneration.
In January 2023, RegenOrthoSport, an orthopedic clinic, in Mumbai, Maharashtra, announced that it had received an approval from the National Ethics Committee Registry for Biomedical and Health Research (NECRBHR), under the Ministry of Health and Family Welfare for the use of Autologous Bone Marrow Aspirate Concentrate (BMAC) and Platelet Rich Plasma (PRP) on patients affected with musculoskeletal disorders
In May 2022, Ester Medical, a pharmaceutical company announced that it had signed an agreement with Aesthetic Management for exclusive long-term marketing and distribution of Eclipse PRP and Tropocells in the U.S. market.